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Reverse cholesterol transport (RCT), a key function of high-density lipoproteins (HDL), prevents excess
cholesterol in tissues. A study in this issue (Lim et al., 2013) suggests that lymphatic vessels are critical for
normal RCT and mediate the active trans-endothelial transport of HDL via the HDL receptor SR-BI.Cells require cholesterol for viability.
However, excess cholesterol can be toxic
to cells and therefore cells have evolved
mechanisms to promote cholesterol
efflux in a regulated manner. Cellular
cholesterol is effluxed to ‘‘acceptors’’
that are generally in the family of high-
density lipoproteins (HDL), including its
major protein apolipoprotein A-I (apoA-I).
Once cellular cholesterol is effluxed to
HDL, it is returned to liver for excretion in
the bile in a process known as ‘‘reverse
cholesterol transport (RCT)’’ (Rader
et al., 2009). RCT is not only a physiolog-
ical process required for maintaining
cholesterol homeostasis but also has po-
tential protective effects on atheroscle-
rosis. While substantial attention has
been focused on the initial pathways of
cellular cholesterol efflux and on the fate
of HDL cholesterol within the blood,
much less is known about the fate of the
newly effluxed cholesterol and how it
reaches the blood. Lim et al. (2013) report
that impaired lymphatic function reduces
the efficiency of RCT and that lymphatic
endothelium actively transports HDL
particles.
Lymphatic vessels transport interstitial
fluid and cells back to the blood, coordi-
nating adaptive immune responses, and
carry lipids absorbed from the intestine
to the blood. Interstitial and lymphatic
fluid contains HDL and apoA-I (Sloop
et al., 1987), and lymphatics have long
been suspected to play an important
role in transporting newly effluxed
cholesterol from the site of efflux to the
blood (Sloop et al., 1987). However, since
molecular tools to investigate lymphatic
vessel function were only recently devel-
oped, the physiological roles for this
vascular network remain to be rigorouslydefined. Effects of lymphatic loss of func-
tion on lipid metabolism, such as obesity
and the deposition of fat in edematous
tissue, have been observed in mice lack-
ing lymphatic function due to genetic
(e.g., loss of the lymphatic endothelial
transcription factor PROX1 [Harvey
et al., 2005]) or mechanical reasons
(Rutkowski et al., 2006), and in humans
with chronic lymphedema (Schirger
et al., 1962). Lim et al. (2009) reported
in an earlier study that hypercholesterol-
emic apoE-deficient mice have abnormal
lymphatic function that results in excess
accumulation of cholesterol in the periph-
ery. These studies hinted at important
connections between obesity, choles-
terol, and lymphatic function, but clear
molecular links were not established.
Lim et al. (2013) now establish a
convincing causal connection between
lymphatic vessel function and HDL trans-
port and provide a molecular basis for
this observation. By adapting an estab-
lished method for assessing macrophage
RCT in vivo (Rader et al., 2009), they show
that after injection of macrophages
labeled with fluorescent cholesterol into
the footpad, apoE-deficient mice have
markedly impaired cholesterol transport
into plasma and liver. They further
demonstrate that treatment of apoE-
deficient mice with ezetimibe, which
reduces plasma cholesterol, or local in-
jection of VEGF-C to promote lymphatic
formation, improves lymphatic function,
reduces peripheral cholesterol accumula-
tion, and, most compellingly, promotes
RCT. In order to test whether this process
is dependent on HDL-mediated transport,
the authors show that labeled HDL in-
jected into the footpad is rapidly taken
up by lymphatic vessels and eventuallyCell Metabolistransported to the blood—and that
surgical disruption of lymphatic drainage
markedly impairs entry of injected HDL
into the blood. Furthermore, apoE-defi-
cient mice exhibit a defect in transport
of HDL into lymphatics that is improved
by both ezetimibe and VEGF-C treatment.
These studies clearly implicate lymphatic
vessels in mediating the return of macro-
phage-derived cholesterol and interstitial
fluid HDL to the circulation, reliably indi-
cating an important role in RCT.
The authors then investigate whether
lymphatic vessels are simply conduits
that passively collect the interstitial fluid
HDL into lymph, or whether they actively
participate in HDL transport. Using
lymphatic endothelial cells (LECs), they
find evidence for expression of the
classic HDL receptor scavenger receptor
class BI (SR-BI) (Figure 1). SR-BI not
only promotes uptake of HDL cholesterol
into hepatocytes but also has HDL trans-
port functions in other cell types, including
vascular endothelial cells. Lim et al. (2013)
show that LECs internalize and transcy-
tose HDL and that this process is blocked
by inhibition of SR-BI with siRNA, an anti-
body, or a small molecule. Compellingly,
after injection of cholesterol-labeled
macrophages in the footpad, appearance
of labeled cholesterol in lymph, lymph
nodes, and plasma is markedly dimin-
ished if SR-BI is inhibited by antibody
treatment or deleted genetically. These
findings suggest that the lymphatic ves-
sels are not mere passive conduits but
function as active biological transporters
of HDL from interstitial fluid into lymph,
thus actively regulating RCT.
Lim et al. (2013) have thus identified a
novel role for lymphatic vessels in RCT
that may connect lymphatic function tom 17, May 7, 2013 ª2013 Elsevier Inc. 627
Figure 1. Role of Lymphatics in Uptake and Transport of Interstitial Fluid HDL
HDL promotes efflux of cholesterol from macrophages, here shown conceptually within the atheroscle-
rotic arterial plaque (not directly demonstrated in the current article by Lim et al. [2013]). HDL in interstitial
fluid in the adventitia is actively transported by the lymphatic endothelium via SR-BI into the lumen of
lymphatic vessels, whereupon it is ultimately returned to the plasma compartment.
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several important questions remain to be
fully addressed. For example, how quanti-
tatively important is lymphatic function
in reverse cholesterol transport? The
authors make extensive use of apoE-
deficient animals to address this ques-
tion. However, the basis for the observed
lymphatic defects in apoE-deficient mice
is not yet clear, and it would be important
to address the role of lymphatics in
cholesterol transport using mice lacking
lymphatic function through a mechanism
independent of cholesterol metabolism,
for example with partial loss of VEGFC-
VEGFR3 signaling or PROX1. Along the
same lines, SR-BI is a strong candidate
mechanism for HDL uptake and transport
by lymphatic vessels, but additional
studies such as selective loss of SR-B1
in lymphatic endothelial cells in vivo are
required to confirm that HDL transport
by lymphatics reflects direct uptake by
lymphatic endothelium rather than pas-628 Cell Metabolism 17, May 7, 2013 ª2013sive movement with interstitial fluid or an
indirect cellular mechanism. Importantly,
what is the relationship of lymphatic
function to atherosclerosis (Figure 1)? It
was previously shown that macrophages
and dendritic cells can egress from the
regressing atherosclerotic plaque via the
lymphatic system (Llodra´ et al., 2004);
now, it appears that HDL itself may do
the same. Might conditions of impaired
lymphatic function exacerbate athero-
sclerosis—and, conversely, might treat-
ment to improve lymphatic function be
a novel therapeutic approach to athero-
sclerotic disease?
Several recent events have created
substantial uncertainty regarding the
clinical benefits of raising plasma levels
of HDL cholesterol to reduce risk of
atherosclerotic vascular disease (Rader
and Tall, 2012). These include human
genetic studies showing that genes influ-
encing HDL-C levels have a poor relation-
ship to vascular disease, as well asElsevier Inc.several failed clinical trials of HDL-raising
drugs. Nevertheless, there remains sub-
stantial interest in the therapeutic target-
ing of cholesterol efflux and RCT as a
strategy to combat atherosclerosis
(Degoma and Rader, 2011). The concept
that lymphatic vessels play an important
biological role in this process opens new
vistas for therapeutic intervention. A fact
brought home strongly by these exciting
new studies is that there remains much
that we don’t know about the roles
of lymphatic vessels in physiologic and
pathologic states. Further studies of
mouse models and the development
of new tools to observe and measure
lymphatic function in human patients are
certain to reveal additional dynamic roles
for lymphatic vessels and perhaps unex-
pected strategies for the treatment of
common human diseases.REFERENCES
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